236 related articles for article (PubMed ID: 17426060)
1. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
2. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
3. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
4. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
5. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
Buettner R; Mesa T; Vultur A; Lee F; Jove R
Mol Cancer Res; 2008 Nov; 6(11):1766-74. PubMed ID: 19010823
[TBL] [Abstract][Full Text] [Related]
7. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
[TBL] [Abstract][Full Text] [Related]
8. [SRC kinases in tumor therapy].
Dempke W; Zippel R
Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
12. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
13. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Ahluwalia MS; de Groot J; Liu WM; Gladson CL
Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
15. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Goc A; Al-Husein B; Katsanevas K; Steinbach A; Lou U; Sabbineni H; DeRemer DL; Somanath PR
Oncotarget; 2014 Feb; 5(3):775-87. PubMed ID: 24519956
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
18. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in solid tumors.
Kim LC; Rix U; Haura EB
Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
